High-throughput hit finding and compound-profiling technologies for academic drug discovery

Drug discovery within Academia is now firmly established and typically uses technologies that are based on historical Pharmaceutical industry paradigms. New technologies, now being adopted by the Pharmaceutical industry, offer advantages over traditional screening and compound-profiling techniques. These approaches mark a departure from the ‘one gene, one protein, one target, one compound’ model. This review covers the benefits which are achievable if academic drug discovery organisations were to look beyond microplate-based screening.

Section editors:Phil Gribbon – European ScreeningPort, Hamburg, GermanyKelvin Lam – Harvard University, Cambridge, MA, USA